Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives
Dentsply Sirona (Nasdaq: XRAY) has announced its decision to retain Wellspect Healthcare as a subsidiary following a comprehensive strategic review initiated in February 2025. The company determined that keeping Wellspect within its portfolio would create more value for stockholders than other alternatives, including potential sale options.
Wellspect, a leading provider of bladder and bowel care products with a 40-year history, has demonstrated strong performance with mid-single digit growth in 2024. The business operates in the continence care market, which has an estimated $2 billion addressable market. CEO Dan Scavilla emphasized Wellspect's position as a category leader with strong cash flow generation and significant market potential.
Dentsply Sirona (Nasdaq: XRAY) ha annunciato la decisione di mantenere Wellspect Healthcare come controllata dopo un'analisi strategica approfondita avviata nel febbraio 2025. L'azienda ha ritenuto che mantenere Wellspect nel proprio portafoglio creerebbe maggiore valore per gli azionisti rispetto ad altre alternative, incluse eventuali cessioni.
Wellspect, fornitore di riferimento per prodotti di cura della vescica e dell'intestino con una storia di 40 anni, ha registrato solide performance con una crescita a metà cifra singola nel 2024. L'attività opera nel mercato della cura della continenza, stimato in un mercato indirizzabile di 2 miliardi di dollari. Il CEO Dan Scavilla ha sottolineato la posizione di leader di categoria di Wellspect, la forte generazione di cassa e il significativo potenziale di mercato.
Dentsply Sirona (Nasdaq: XRAY) ha anunciado su decisión de mantener a Wellspect Healthcare como subsidiaria tras una revisión estratégica exhaustiva iniciada en febrero de 2025. La compañía determinó que conservar Wellspect en su cartera generaría más valor para los accionistas que otras alternativas, incluidas posibles ventas.
Wellspect, proveedor líder de productos para el cuidado de la vejiga y el intestino con una trayectoria de 40 años, mostró un sólido desempeño con un crecimiento de cifra media en 2024. La empresa opera en el mercado del cuidado de la continencia, con un mercado direccionable estimado en 2.000 millones de dólares. El CEO Dan Scavilla destacó la posición de Wellspect como líder de categoría, su fuerte generación de caja y su importante potencial de mercado.
Dentsply Sirona (Nasdaq: XRAY)는 2025년 2월에 시작한 종합적인 전략 검토 후 Wellspect Healthcare를 자회사로 유지하기로 결정했다고 발표했습니다. 회사는 Wellspect를 포트폴리오에 유지하는 것이 잠재적 매각을 포함한 다른 대안보다 주주 가치를 더 높일 것이라고 판단했습니다.
40년의 역사를 가진 방광 및 장 관리 제품의 선도 기업인 Wellspect는 2024년 중간 단위 수치의 성장으로 견조한 실적을 보였습니다. 이 사업은 약20억 달러의 주소 지정 가능 시장으로 추정되는 실금(요실금) 관리 시장에서 운영됩니다. CEO인 Dan Scavilla는 Wellspect가 범주 선도자로서 강한 현금 흐름을 창출하고 상당한 시장 잠재력을 지녔다고 강조했습니다.
Dentsply Sirona (Nasdaq: XRAY) a annoncé sa décision de conserver Wellspect Healthcare comme filiale à l'issue d'un examen stratégique approfondi lancé en février 2025. La société a estimé que maintenir Wellspect dans son portefeuille créerait davantage de valeur pour les actionnaires que d'autres options, y compris une éventuelle cession.
Wellspect, fournisseur de premier plan de produits pour les soins de la vessie et des intestins, fort d'une expérience de 40 ans, a enregistré de bonnes performances avec une croissance à un chiffre moyen en 2024. L'activité évolue sur le marché des soins de la continence, estimé à un marché adressable de 2 milliards de dollars. Le PDG Dan Scavilla a souligné la position de leader de Wellspect, sa forte génération de trésorerie et le potentiel de marché significatif.
Dentsply Sirona (Nasdaq: XRAY) hat nach einer umfassenden strategischen Überprüfung, die im Februar 2025 begonnen wurde, beschlossen, Wellspect Healthcare als Tochtergesellschaft zu behalten. Das Unternehmen kam zu dem Schluss, dass die Beibehaltung von Wellspect im Portfolio für die Aktionäre mehr Wert schaffen würde als andere Alternativen, einschließlich eines möglichen Verkaufs.
Wellspect, ein führender Anbieter von Blasen- und Darmversorgungsprodukten mit einer 40-jährigen Geschichte, zeigte eine solide Entwicklung mit einem Wachstum im mittleren einstelligen Bereich im Jahr 2024. Das Geschäft ist im Kontinenzmarkt tätig, der ein geschätztes adressierbares Marktvolumen von 2 Milliarden US-Dollar aufweist. CEO Dan Scavilla betonte Wellspects Stellung als Kategorienführer, die starke Cashflow-Generierung und das erhebliche Markpotenzial.
- None.
- Strategic review process did not result in an attractive sale option
- Company acknowledges need for improvement in customer experience and operational performance
Insights
Dentsply Sirona's decision to retain Wellspect reflects confidence in its long-term value despite likely receiving underwhelming acquisition offers.
Dentsply Sirona has concluded its seven-month strategic review of Wellspect Healthcare, opting to retain the continence care business rather than divest it. This decision comes after engaging with multiple potential buyers but ultimately determining that keeping Wellspect within its portfolio would create more stockholder value.
The language in this announcement suggests Dentsply Sirona likely received acquisition offers that were below their internal valuation of Wellspect. The business demonstrates several positive attributes: it's described as a category leader in continence care with strong cash flow generation, mid-single digit growth in 2024, and operates in an estimated
While retaining Wellspect might appear contradictory to the company's core dental focus, this decision indicates management sees greater long-term value in maintaining a diversified portfolio than accepting what were likely underwhelming offers. CEO Dan Scavilla, who took the role just last month, signals this is part of a broader strategy reassessment, mentioning the need to improve customer experience and deliver stronger financial performance.
The market will likely view this announcement with mixed sentiment - positively for the recognition of Wellspect's value, but possibly with disappointment that no immediate value was unlocked through a sale. The statement that Wellspect will "continue to play an important role" suggests Dentsply Sirona remains open to divesting this non-core business in the future should more attractive offers materialize.
Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company
CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business (“Wellspect”), which was announced in February 2025. As a part of its review process, Dentsply Sirona considered a range of potential opportunities for Wellspect, including a sale of the business. The Company conducted broad outreach, including engaging with multiple parties regarding their interest in Wellspect.
Following extensive review and deliberation, Dentsply Sirona determined that retaining Wellspect as a subsidiary within its portfolio will create more value for Dentsply Sirona stockholders than the other alternatives available to the Company.
“We are committed to improving patient outcomes and driving long-term value for Dentsply Sirona customers, employees and stockholders. To that end, after executing a comprehensive review of strategic alternatives for Wellspect, we are confident that retaining the business will deliver greater financial and strategic benefits to stockholders than the other options available,” said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. “Wellspect is a category leader in the global continence care market with a high-quality product pipeline, strong cash flow generation and significant untapped market potential. The recent investments we’ve made in Wellspect are generating results, and we believe that the business will continue to play an important role in our strategy to deliver durable, profitable growth across the entire Dentsply Sirona portfolio.”
Scavilla continued, “Since stepping into the CEO role in August, I have met with investors, customers, partners, employees and other stakeholders to understand their perspectives on our business. While it’s clear to me from those discussions that our foundation is solid, it is evident that we need to do more to improve the customer experience and move faster as an organization while delivering stronger financial and operational performance. I look forward to sharing more about our strategic priorities and future growth plans in the months ahead.”
Wellspect is a leading provider of bladder and bowel care products with an over 40-year history. Through its comprehensive portfolio of products and accessories from trusted brands like LoFric® and Navina™, Wellspect has delivered organic sales growth in recent years, including mid-single digit growth in 2024. Wellspect is well-positioned in the large and growing continence care space, which has an estimated
About Dentsply Sirona
Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
Contact Information
Investors:
Wade Moody
Senior Manager, Investor Relations
InvestorRelations@dentsplysirona.com
Press:
Marion Par-Weixlberger
Vice President, Public Relations & Corporate Communications
+43 676 848414588
marion.par-weixlberger@dentsplysirona.com
Forward-Looking Statements and Associated Risks
All statements in this Press Release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.
FAQ
Why did Dentsply Sirona (XRAY) decide to keep Wellspect Healthcare?
What is the market size for Wellspect's continence care business?
How has Wellspect Healthcare performed recently under Dentsply Sirona?
What are Wellspect's main product brands?
When did Dentsply Sirona begin its strategic review of Wellspect?
